EU authorizes remdesivir use against COVID-19

Friday, 03. July 2020 12:42

The European Commission announced on Friday that it gave "a conditional marketing authorization" for the Gilead Sciences Inc.'s medicine remdesivir to be used for treatment against COVID-19.

"Today's authorization of a first medicine to treat COVID-19 is an important step forward in the fight against this virus. We are granting this authorization less than a month after the application was submitted, showing clearly the EU's determination to respond quickly whenever new treatments become available," Commissioner for Health and Food Safety Stella Kyriakides said in a statement.

The Commission noted that the "rolling review procedure" enabled the drug's authorization only a week after the European Medicines Agency's (EMA) had recommended its use in COVID-19 treatment, while the previous procedure required 67 days to pass.

Related Links: Gilead Sciences Inc.
Breaking the News / MS